Q3 2026 Encompass Health Corp Earnings Call

October 29, 2026

Speaker #2: Please stand by. Your meeting is about to begin. Good morning, everyone, and welcome to Encompass Health's third quarter 2026 earnings conference call. At this time, I would like to inform all participants that their lines will be in a listen-only mode.

Operator: Good morning, everyone, and welcome to Encompass Health's Q3 2026 Earnings Conference Call. At this time, I would like to inform all participants that their lines will be in a listen-only mode. After the speaker's remarks, there will be a question and answer period. If you would like to ask a question during this time, please press star one on your telephone keypad.

Speaker #2: After the speaker's remarks, there will be a question and answer period. If you would like to ask a question during this time, please press star one on your telephone keypad.

Operator: You will be limited to one question and one follow-up question. Today's conference call is being recorded. If you have any objections, you may disconnect at this time. I will now turn the call over to Mark Miller, Encompass Health's Chief Investor Relations Officer.

Speaker #2: You will be limited to one question and one follow-up question. Today's conference call is being recorded. If you have any objections, you may disconnect at this time.

Operator: I will now turn the call over to Mark Miller, Encompass Health's Chief Investor Relations Officer.

Speaker #2: I will now turn the call over to Mark Miller, Encompass Health's Chief Investor Relations Officer.

Mark Miller: Thank you, operator, and good morning, everyone. Thank you for joining Encompass Health's Q3 2026 earnings call. Before we begin, if you do not already have a copy, the Q3 earnings release, supplemental information, and related Form 8-K filed with the SEC are available on our website at encompasshealth.com. On page 2 of the supplemental information, you will find the safe harbor statements, which are also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements such as guidance and growth projections, which are subject to risks and uncertainties, many of which are beyond our control.

Speaker #3: Hi. Thank you, operator, and good morning, everyone. Thank you for joining Encompass Health's third quarter 2026 earnings call. Before we begin, if you do not already have a copy, the third quarter earnings release supplemental information and related Form 8K filed with the SEC are available on our website at encompasshealth.com.

Mark Miller: On page 2 of the supplemental information, you will find the safe harbor statements, which are also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements such as guidance and growth projections, which are subject to risks and uncertainties, many of which are beyond our control.

Speaker #3: On page two of the supplemental information, you will find the safe harbor statements which are also set forth in greater detail on the last page of the earnings release.

Speaker #3: During the call, we will make forward-looking statements such as guidance and growth projections which are subject to risks and uncertainties many of which are beyond our control.

Mark Miller: Certain risks and uncertainties, like those relating to regulatory developments as well as volume, bad debt, and cost trends that could cause actual results to differ materially from our projections, estimates, and expectations are discussed in the company's SEC filings, including the earnings release and related Form 8-K, the Form 10-K for the year ended 31 December 2025, and the Form 10-Q for the quarters ended 31 March 2026, 30 June 2026, and 30 September 2026 when filed. We encourage you to read them. You are cautioned not to place undue reliance on the estimates, projections, guidance, and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures.

Speaker #3: Certain risks and uncertainties like those relating to regulatory developments as well as volume bad debt and cost trends that could cause actual results to differ materially from our projections estimates and expectations are discussed in the company's SEC filings including the earnings release and related Form 8K, the Form 10K for the year ending December 31st, 2025, and the Form 10Q for the quarters ended March 31st, 2026, June 30th, 2026, and September 30th, 2026, when filed.

Speaker #3: We encourage you to read them. Your caution not to place undue reliance on the estimates projections guidance and other forward-looking information presented which are based on current estimates of future events and speak only as of today.

Mark Miller: You are cautioned not to place undue reliance on the estimates, projections, guidance, and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures.

Speaker #3: We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures.

Mark Miller: For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the supplemental information, at the end of the earnings release, and as part of the Form 8-K filed yesterday with the SEC, all of which are available on our website. I would like to remind everyone that we will adhere to the one question and one follow-up question rule to allow everyone to submit a question. If you have additional questions, please feel free to put yourself back in the queue. With that, I'll turn the call over to President and Chief Executive Officer, Mark Tarr.

Speaker #3: For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the supplemental information at the end of the earnings release and as part of the Form 8K filed yesterday with the SEC, all of which are available on our website.

Speaker #3: I would like to remind everyone that we will adhere to the one question and one follow-up question rule to allow everyone to submit a question.

Speaker #3: If you have additional questions, please feel free to put yourself back in the queue. With that, I'll turn the call over to President and Chief Executive Officer Mark Tarr.

Mark Tarr: Mark, thank you, and good morning, everyone. We're very pleased with our Q3 results. As revenue grew 8.9%, adjusted EBITDA increased 15.5%, and adjusted EPS increased 23.6%. For the first nine months of 2026, revenue rose 9.2%, adjusted EBITDA increased 11.9%, and adjusted EPS was up 17%. Based primarily on our Q3 results, we are again raising our guidance for 2026. We achieved these results while once again delivering outstanding patient outcomes. Our Q3 discharge to community rate was 84.7%, discharge to acute rate was 8.4%, and discharge to SNF rate was 6.2%. Our performance on each of these quality metrics continues to exceed industry averages. Our hospitals continue to be recognized for the outstanding clinical care we provide. Newsweek recently named Encompass Health as America's Most Awarded Leader in Inpatient Rehabilitation for the seventh consecutive year.

Speaker #4: Mark, thank you. And good morning, everyone. We're very pleased with our third quarter results. As revenue grew 8.9%, adjusted EBITDA increased 15.5%, and adjusted EPS increased 23.6%.

Speaker #4: For the first nine months of 2026, revenue rose 9.2%, adjusted EBITDA increased 11.9%, and adjusted EPS was up 17%. Based primarily on our Q3 results, we are again raising our guidance for 2026.

Speaker #4: We achieved these results while once again delivering outstanding patient outcomes. Our Q3 discharge community rate was 84.7%, discharged to acute rate was 8.4%, and discharge to sniff rate was 6.2%.

Mark Tarr: Our Q3 discharge to community rate was 84.7%, discharge to acute rate was 8.4%, and discharge to SNF rate was 6.2%. Our performance on each of these quality metrics continues to exceed industry averages. Our hospitals continue to be recognized for the outstanding clinical care we provide. Newsweek recently named Encompass Health as America's Most Awarded Leader in Inpatient Rehabilitation for the seventh consecutive year.

Speaker #4: Our performance on each of these quality metrics continues to exceed industry averages. Our hospitals continue to be recognized for the outstanding clinical care we provide.

Speaker #4: Newsweek recently named Encompass Health as America's most awarded leader in inpatient rehabilitation for the seventh consecutive year. Also, NRC Health, a leading provider of patient experience data, recognized Encompass Health with the 2026 NRC Health Excellence in Patient Experience Award for the second consecutive year.

Mark Tarr: Also, NRC Health, a leading provider of patient experience data, recognized Encompass Health with the 2026 NRC Health Excellence in Patient Experience Award for the second consecutive year, placing us among the top 3 large health systems nationwide for patient experience. Our investments in professional growth and development programs for our clinicians continue to enhance our abilities to serve high acuity, medically complex patients. Encompass Health holds 408 Joint Commission disease-specific certifications, including 150 Joint Commission stroke certifications. This represents approximately 65% of total stroke certifications among all providers. in August 2026, the American Heart Association and American Stroke Association reaffirmed the importance of inpatient rehabilitation facilities in their updated 2026 stroke rehabilitation guideline, recommending IRF care over skilled nursing facilities for eligible stroke patients when both settings are available.

Speaker #4: Placing us among the top three large health systems nationwide for patient experience. Our investments in professional growth and development programs for our clinicians continue to enhance our abilities to serve high-acuity medically complex patients.

Mark Tarr: Encompass Health holds 408 Joint Commission disease-specific certifications, including 150 Joint Commission stroke certifications. This represents approximately 65% of total stroke certifications among all providers. in August 2026, the American Heart Association and American Stroke Association reaffirmed the importance of inpatient rehabilitation facilities in their updated 2026 stroke rehabilitation guideline, recommending IRF care over skilled nursing facilities for eligible stroke patients when both settings are available.

Speaker #4: Encompass Health holds 408 Joint Commission disease-specific certifications, including 150 Joint Commission stroke certifications. This represents approximately 65% of total stroke certifications among all providers.

Speaker #4: In August 2026, the American Heart Association and American Stroke Association reaffirmed the importance of inpatient rehabilitation facilities in their updated 2026 stroke rehabilitation guideline recommending ERF care over skilled nursing facilities for eligible stroke patients when both settings are available.

Mark Tarr: The recommendation is supported by evidence showing greater functional improvement and higher rates of discharge back to the community following IRF care. We treat more stroke patients than any other inpatient rehabilitation provider. Through the first 3 quarters of 2026, we treated 37,620 patients recovering from a stroke, comprising approximately 18% of our patient mix. We will continue to put our resources to work to help stroke and other vulnerable patients regain their independence and return to the activities that matter most to them. Demand for inpatient rehabilitation services remains strong and is growing. We continue to invest in capacity additions to help address this underserved market. In Q3, we opened a new 50-bed hospital in Norristown, Pennsylvania, and added 31 beds to existing hospitals. Through the third quarter, we opened 4 hospitals with a total of 189 beds and added 85 beds to existing hospitals.

Speaker #4: The recommendation is supported by evidence showing greater functional improvement and higher rates of discharge back to the community following ERF care. We treat more stroke patients than any other inpatient rehabilitation provider.

Speaker #4: Through the first three quarters of 2026, we treated 37,620 patients recovering from a stroke. Comprising approximately 18% of our patient mix. We will continue to put our resources to work to help stroke and other vulnerable patients regain their independence and return to the activities that matter most to them.

Mark Tarr: We will continue to put our resources to work to help stroke and other vulnerable patients regain their independence and return to the activities that matter most to them. Demand for inpatient rehabilitation services remains strong and is growing. We continue to invest in capacity additions to help address this underserved market. In Q3, we opened a new 50-bed hospital in Norristown, Pennsylvania, and added 31 beds to existing hospitals. Through the third quarter, we opened 4 hospitals with a total of 189 beds and added 85 beds to existing hospitals.

Speaker #4: Demand for inpatient rehabilitation services remains strong and is growing. We continue to invest in capacity additions to help address this underserved market. In Q3, we opened a new 50-bed hospital in Norristown, Pennsylvania, and added 31 beds to existing hospitals.

Speaker #4: Through the third quarter, we opened four hospitals with a total of 189 beds and added 85 beds to existing hospitals. Earlier this month, we opened two additional 50-bed hospitals: one in Bangor, Maine, and one in San Antonio, Texas, and added 60 beds to existing hospitals.

Mark Tarr: Earlier this month, we opened 2 additional 50-bed hospitals, one in Bangor, Maine, and one in San Antonio, Texas, and added 60 beds to existing hospitals. Over the balance of the year, we intend to open 2 more hospitals with a total of 100 beds and add up to 45 beds to existing hospitals. We maintain an active pipeline of new hospital development projects while also executing on bed expansion opportunities as warranted by occupancy trends and market dynamics. Our pipeline of announced new hospital projects with opening dates beyond 2026 currently consists of 15 hospitals with 654 beds. This includes our first 2 small format hospitals, Conroe, Texas, and Richmond, Texas, both of which will be additive to our Houston market presence and serve as an exemplar of the hub and spoke strategy we have previously discussed.

Speaker #4: Over the balance of the year, we intend to open two more hospitals with a total of 100 beds and add up to 45 beds to existing hospitals.

Speaker #4: We maintain an active pipeline of new hospital development projects, while also executing on bed expansion opportunities as warranted by occupancy trends and market dynamics.

Mark Tarr: Our pipeline of announced new hospital projects with opening dates beyond 2026 currently consists of 15 hospitals with 654 beds. This includes our first 2 small format hospitals, Conroe, Texas, and Richmond, Texas, both of which will be additive to our Houston market presence and serve as an exemplar of the hub and spoke strategy we have previously discussed.

Speaker #4: Our pipeline of announced new hospital projects with opening dates beyond 2026 currently consists of 15 hospitals with 654 beds. This includes our first two small-format hospitals: Conroe, Texas, and Richmond, Texas, both of which will be additive to our Houston market presence and serve as an exemplar of the hub and spoke strategy we have previously discussed.

Mark Tarr: We anticipate additional projects will be announced over the balance of the year. We also continue to expect to add 150 to 200 beds to existing hospitals in 2027. On 1 October, North Carolina's repeal of its certificate of need law became effective. As we have previously discussed, North Carolina has highly favorable population growth and demographic characteristics, and our assessment indicates a large underserved market for IRF services. We currently operate one hospital in North Carolina and have thus far prioritized 15 markets for development. We currently have 6 real estate parcels under contract. Now I'll turn it over to Doug.

Speaker #4: We anticipate additional projects will be announced over the balance of the year. We also continue to expect to add 150 to 200 beds to existing hospitals in 2027.

Speaker #4: On October 1st, North Carolina’s repeal of its certificate of need law became effective. As we have previously discussed, North Carolina has highly favorable population growth and demographic characteristics, and our assessment indicates a large underserved market for ERF services.

Mark Tarr: As we have previously discussed, North Carolina has highly favorable population growth and demographic characteristics, and our assessment indicates a large underserved market for IRF services. We currently operate one hospital in North Carolina and have thus far prioritized 15 markets for development. We currently have 6 real estate parcels under contract. Now I'll turn it over to Doug.

Speaker #4: We currently operate one hospital in North Carolina and have thus far prioritized fifteen markets for development. We currently have six real estate parcels under contract.

Speaker #4: Now I'll turn it over to Doug.

Doug Coltharp: Thank you, Mark, and good morning, everyone. The Q3 revenue increase of 8.9% was driven by 5.7% discharge growth and a 4% increase in net revenue per discharge. Net revenue per discharge again benefited from higher patient acuity. Bad debt expense in Q3 was 2.7%. The increase over last year is primarily due to a billing and collection disruption issue following a system conversion in Q2 of 2026. This was a one-off issue, and we expect bad debt expense as a percent of revenue in Q4 to normalize in the recent historical range of 2% to 2.5%. Q3 Medicaid supplemental payments decreased by $10 million from Q3 2025. Recall that Q3 2025 included $10.8 million of net provider tax revenue owing largely to retroactive Medicaid supplemental payments.

Speaker #5: Thank you, Mark, and good morning, everyone. The Q3 revenue increase of 8.9% was driven by 5.7% discharge growth and a 4% increase in net revenue per discharge.

Speaker #5: Net revenue per discharge again benefited from higher patient acuity. Bad debt expense in Q3 was 2.7%. The increase over last year is primarily due to a billing and collection disruption issue following a system conversion in Q2 of 2026.

Doug Coltharp: This was a one-off issue, and we expect bad debt expense as a percent of revenue in Q4 to normalize in the recent historical range of 2% to 2.5%. Q3 Medicaid supplemental payments decreased by $10 million from Q3 2025. Recall that Q3 2025 included $10.8 million of net provider tax revenue owing largely to retroactive Medicaid supplemental payments.

Speaker #5: This was a one-off issue and we expect bad debt expense as a percent of revenue in Q4 to normalize in the recent historical range of 2 to 2.5%.

Speaker #5: Q3 Medicaid supplemental payments decreased by $10 million from Q3 '25. Recall that Q3 '25 included 10.8 million of net provider tax revenue owing largely to retroactive Medicaid supplemental payments.

Doug Coltharp: In Q3 2026, we reversed $9.2 million of previously accrued supplemental payments within our other revenue category related to the anticipated approval by CMS of the Florida fiscal year 2026 Medicaid state-directed payment program. The Florida fiscal year 2026 program is still pending approval from CMS, and as the fiscal year ended 30 September, we deemed it appropriate to make this adjustment. We also reversed $3.4 million of accrued provider tax expense within our other operating expenses related to the 2026 Florida program. Q3 adjusted EBITDA increased 15.5% to $346.6 million, even as we absorbed an $11.5 million year-over-year decrease in net provider tax contribution. Through the first three quarters of 2026, the adjusted EBITDA contribution from net provider taxes was $600,000, and that compares to $18.1 million for the comparable 2025 period.

Speaker #5: In Q3 '26, we reversed 9.2 million of previously accrued supplemental payments within our other revenue category related to the anticipated approval by CMS of the Florida fiscal year 2026 Medicaid state-directed payment program.

Speaker #5: The Florida fiscal year '26 program is still pending approval from CMS. And as the fiscal year ended September 30th, we deemed it appropriate to make this adjustment.

Doug Coltharp: We also reversed $3.4 million of accrued provider tax expense within our other operating expenses related to the 2026 Florida program. Q3 adjusted EBITDA increased 15.5% to $346.6 million, even as we absorbed an $11.5 million year-over-year decrease in net provider tax contribution. Through the first three quarters of 2026, the adjusted EBITDA contribution from net provider taxes was $600,000, and that compares to $18.1 million for the comparable 2025 period.

Speaker #5: We also reversed 3.4 million of accrued provider tax expense within our other operating expenses related to the 2026 Florida program. Q3 adjusted EBITDA increased 15.5% to $346.6 million even as we absorbed an 11.5 million year-over-year decrease in net provider tax contribution.

Speaker #5: Through the first three quarters of 2026, the adjusted EBITDA contribution from net provider taxes was $600,000, and that compares to 18.1 million for the comparable 2025 period.

Doug Coltharp: In our Q2 update, we had revised our expectation for the 2026 net provider taxes contribution to our adjusted EBITDA to approximately $10 million. This was based primarily on the Florida fiscal year 2025 Medicaid state-directed payment program approved by CMS in May of 2026. Given the pending status of the fiscal year 2026 program and the related adjustments to our accruals, which I just reviewed, we now expect the 2026 net contribution to adjusted EBITDA to be approximately $3 million. Q3 SWB per FTE increased 3.8%, in part driven by increased participation in our career ladder programs, partially offset by declines in premium labor and medical plan costs. Premium labor costs comprised of contract labor and sign-on and shift bonuses declined $3.9 million from Q3 2025 to $23.1 million.

Speaker #5: In our Q2 update, we had revised our expectation for the 2026 net provider taxes contribution to our adjusted EBITDA to approximately $10 million. This was based primarily on the Florida fiscal year 2025 Medicaid state-directed payment program approved by CMS in May of 2026.

Doug Coltharp: Given the pending status of the fiscal year 2026 program and the related adjustments to our accruals, which I just reviewed, we now expect the 2026 net contribution to adjusted EBITDA to be approximately $3 million. Q3 SWB per FTE increased 3.8%, in part driven by increased participation in our career ladder programs, partially offset by declines in premium labor and medical plan costs. Premium labor costs comprised of contract labor and sign-on and shift bonuses declined $3.9 million from Q3 2025 to $23.1 million.

Speaker #5: Given the pending status of the fiscal year 2026 program and the related adjustments to our accruals, which I just reviewed, we now expect the 2026 net contribution to adjusted EBITDA to be approximately $3 million.

Speaker #5: Q3 SWB per FTE increased 3.8% in part driven by increased participation in our career ladder programs partially offset by declines in premium labor and medical plan costs.

Speaker #5: Premium labor costs comprised of contract labor and sign-on shift bonuses declined 3.9 million from Q3 '25 to 23.1 million. This marks 16 consecutive quarters of year-over-year reductions in premium labor spend even as capacity and patient volumes have grown substantially.

Doug Coltharp: This marks 16 consecutive quarters of year-over-year reductions in premium labor spend, even as capacity and patient volumes have grown substantially. Contract labor FTEs as a percent of total FTEs was 0.9%, an improvement of 30 basis points from Q3 2025, and our lowest level since Q4 of 2020. Q3 net pre-opening and ramp-up costs were $4.9 million, flat from Q3 2025, and were $15.8 million on a year-to-date basis, compared to $11 million through Q3 2025. Based on the incurrence to date and our projection for the balance of the year, we now expect net pre-opening and ramp-up costs of $20 to 24 million for 2026. Adjusted free cash flow for the first nine months of 2026 was $634.2 million, an 8.9% increase from the comparable period in 2025.

Speaker #5: Contract labor FTEs as a percent of total FTEs was 0.9% and improvement of 30 basis points from Q3 '25 and our lowest level since Q4 of 2020.

Doug Coltharp: Q3 net pre-opening and ramp-up costs were $4.9 million, flat from Q3 2025, and were $15.8 million on a year-to-date basis, compared to $11 million through Q3 2025. Based on the incurrence to date and our projection for the balance of the year, we now expect net pre-opening and ramp-up costs of $20 to 24 million for 2026. Adjusted free cash flow for the first nine months of 2026 was $634.2 million, an 8.9% increase from the comparable period in 2025.

Speaker #5: Q3 net pre-opening and ramp-up costs were $4.9 million, flat from Q3 '25, and were $15.8 million on a year-to-date basis compared to $11 million through Q3 '25.

Speaker #5: Based on the incurrence to date and our projection for the balance of the year, we now expect net pre-opening and ramp-up costs of $20 to $24 million for 2026.

Speaker #5: Adjusted free cash flow for the first nine months of 2026 was $634.2 million and $8.9% increase from the comparable period in 2025. During Q3, we repurchased approximately $495,000 shares of our common stock for a total of $57.9 million bringing our year-to-date total share repurchase to approximately $1.91 million shares and $203.7 million.

Doug Coltharp: During Q3, we repurchased approximately 495,000 shares of our common stock for a total of $57.9 million, bringing our year-to-date total share repurchase to approximately 1.91 million shares and $203.7 million. We also declared a cash dividend of $0.21 per share, which was paid earlier this month. During Q3, we issued an incremental $100 million of senior notes as an add-on to our 5.875% notes due in 2034, bringing the total amount of that note series to $600 million. Our leverage and liquidity remained very favorable. Net leverage at quarter end was 1.8 times, and we ended the quarter with approximately $870 million available on our $1 billion revolving credit facility. As Mark mentioned, we have again raised our 2026 guidance as follows.

Speaker #5: We also declared a cash dividend of $21 cents per share which was paid earlier this month. During Q3, we issued an incremental $100 million of senior notes as an add-on to our 5.875% notes due in 2034 bringing the total amount of that note series to $600 million.

Doug Coltharp: During Q3, we issued an incremental $100 million of senior notes as an add-on to our 5.875% notes due in 2034, bringing the total amount of that note series to $600 million. Our leverage and liquidity remained very favorable. Net leverage at quarter end was 1.8 times, and we ended the quarter with approximately $870 million available on our $1 billion revolving credit facility. As Mark mentioned, we have again raised our 2026 guidance as follows.

Speaker #5: Our leverage and liquidity remained very favorable. Net leverage at quarter-end was 1.8 times and we ended the quarter with approximately $870 million available on our $1 billion revolving credit facility.

Speaker #5: As Mark mentioned, we have again raised our 2026 guidance as follows: We now expect net operating revenue of $6.45 to $6.5 billion and adjusted EBITDA of $1.395 to $1.415 billion.

Doug Coltharp: We now expect net operating revenue of $6.45 billion to $6.5 billion, adjusted EBITDA of $1.395 billion to $1.415 billion, and adjusted earnings per share of $6.23 to $6.37. The considerations underlying our guidance can be found on page 11 of the supplemental slides. With that, we will open the line to Q&A.

Speaker #5: And adjusted earnings per share of $6.23 to $6.37. The considerations underlying our guidance can be found on page 11 of the supplemental slides. With that, we'll open the lines for Q&A.

Operator: Thank you. At this time, if you would like to ask a question, please press star one on your keypad now. To remove yourself from the queue, press star two. Once again, that is star one to ask a question. We will take our first question from Pito Chickering with Deutsche Bank. Your line is open.

Speaker #4: Thank you. At this time, if you would like to ask a question, please press star 1 on your keypad now. To remove yourself from the queue, press star 2.

Speaker #4: Once again, that is star 1 to ask a question. And we'll take our first question from Peto Chickering with Deutsche Bank. Your line is open.

Doug Coltharp: Morning, Pito.

Pito Chickering: Hey, good morning.

Speaker #5: Good morning, Peto.

Doug Coltharp: Good morning.

Pito Chickering: Good morning, guys. Nice quarter. I know you weren't giving out 2027 guidance yet, but can you help us walk us through the known headwinds and tailwinds for next year as you do your modeling, specifically in areas like startup losses from the hospitals opening up, managed care pricing, because you just raised that this quarter, your VA penetration, and then anything around labor and turnover that we should be thinking about?

Speaker #6: Good morning, guys. Nice quarter. I know you aren't giving out 2027 guidance yet, but can you help walk us through the known headwinds and tailwinds for next year as we do our modeling?

Speaker #6: Specifically in areas like startup losses from the hospitals opening up, managed care pricing, because you just raised that this quarter. The VA penetration and then any things around labor and turnover that we should be thinking about.

Doug Coltharp: Peter, this is Doug. I'll start on that and then ask Mark and Pat to jump in as they see appropriate. I'd say generally speaking, we think that things are setting up for another solid year in 2027. I won't hit these in the specific order that you mentioned, but I think some things to consider. I just went through quite a few adjustments, and we did the same in Q2 regarding net provider tax impact, predominantly related to the Florida 2025 proposal and then 2026 as well. We're not going to have to repeat those same accrual adjustments in 2027, and that should present some upside there. With regard you asked about pre-opening and ramp-up costs, we've got a comparable number of new hospitals opening next year. I would say that we would expect that number to be plus or minus $20 million.

Speaker #5: Peto, this is Doug. I'll start on that and then ask Mark and Pat to jump in as they see appropriate. I'd say generally speaking, we think that things are setting up for another solid year in 2027.

Speaker #5: I won't address these in the specific order that you mentioned, but I think there are some things to consider. I just went through quite a few adjustments, and we did the same in Q2 regarding net provider tax impact, predominantly related to the Florida '25 proposal and then '26 as well.

Doug Coltharp: We're not going to have to repeat those same accrual adjustments in 2027, and that should present some upside there. With regard you asked about pre-opening and ramp-up costs, we've got a comparable number of new hospitals opening next year. I would say that we would expect that number to be plus or minus $20 million.

Speaker #5: And so we're not going to have to repeat those same accrual adjustments in 2027, and that should present some upside there. With regard, yes, about pre-opening and ramp-up costs, we've got a comparable number of new hospitals opening next year.

Speaker #5: I would say that we would expect that number to be plus or minus $20 million. Some other things to consider, we'll anniversary the last of the four unit closures in late February of next year.

Doug Coltharp: Some other things to consider is we will anniversary the last of the four unit closures in late February of next year. On the labor perspective, we are going to start to anniversary the impact of the increased career ladder participation on SWB. By the same token, I have said this a couple of times before, at some point, we are going to start to realize diminishing returns on the reductions that we have made in premium labor, but we continue to see some opportunity there. From an overall pricing perspective, as we move into Q4 of this year, we are lapping some of the increases that we have seen based on higher patient acuity on revenue per discharge. That is not to suggest that there is not more room to go, but last year in Q4, our net revenue per discharge was at 4.1%, and it stayed right around 4% for the last four quarters.

Speaker #5: On the labor perspective, we're going to start to anniversary the impact of the increased career ladder participation on SWB. By the same token, and I've said this a couple of times before, at some point we're going to start to realize diminishing returns on the reductions that we've made in premium labor, but we continue to see some opportunity there.

Doug Coltharp: From an overall pricing perspective, as we move into Q4 of this year, we are lapping some of the increases that we have seen based on higher patient acuity on revenue per discharge. That is not to suggest that there is not more room to go, but last year in Q4, our net revenue per discharge was at 4.1%, and it stayed right around 4% for the last four quarters. I think those are the primary things that come to mind in terms of considerations.

Speaker #5: From an overall pricing perspective, as we move into Q4 of this year, we're lapping some of the increases that we've seen based on higher patient acuity on revenue per discharge.

Speaker #5: That's not to suggest that there isn't more room to go, but last year in Q4, our net revenue per discharge was at $4.1% and it stayed right around 4% for the last four quarters.

Doug Coltharp: I think those are the primary things that come to mind in terms of considerations.

Speaker #5: I think those are the primary things that come to mind in terms of considerations.

Mark Tarr: Yeah, Peter, it is Mark. I would just say, as we noted in my comments and as we have made a general theme now for the last couple of quarters, adding capacity is a big focus for us. So bringing on additional projects, not only in Q4 this year, but then as it carries over into 2027 with additional beds coming on to existing hospitals. We are going to bring on the first small format hospital next year that we have talked about, as well as additional de novos. So that will be a common theme that will go into 2027, that we have carried off from 2026.

Speaker #3: Yeah, Peto, as Mark, I would just say as we noted in my comments and as we've made a general theme now for the last couple of quarters, I mean, adding capacity is a big focus for us.

Speaker #3: So bringing on the additional projects, not only in Q4 of this year, but then as it carries over into 2027 with additional beds coming on to existing hospitals we're going to bring on the first small format hospital next year that we've talked about.

Speaker #3: As well as additional de novos. So that will be a common theme that we'll go into 2027 that we've carried over from 2026.

Pat Tuer: Hey, Peter, this is Pat. Just a couple of points on VA and then hiring and turnover. VA continues to be a big positive for us. We have now hit our sixth consecutive quarter of at least 20% growth in that segment. We hit 21% growth in Q3. That is on top of 26.4% growth in Q3 of 2025. As well as that is going, there remains a lot of upside. There is a lot of variability between region to region and hospital to hospital in terms of capture of the VA population. So that is something our operators have done a great job with and continue to focus on. You did not ask about this, but as I think about 2027, one of the things that I think deserves to be called out is the success that we have had in the MA admit and appeal strategy, and how we are thinking about expanding that.

Speaker #6: Hey, Peto, this is Pat, just a couple of points on VA and then hiring and turnover. VA, it continues to be a big positive for us.

Speaker #6: We've now hit our sixth consecutive quarter of at least 20% growth in that segment. We hit 21% growth in Q3. That's on top of 26.4% growth in Q3 of 2025.

Speaker #6: As well as that's going, there remains a lot of upside. There's a lot of variability between region to region and hospital to hospital in terms of capture of the VA population, so that's something our operators have done a great job with and continue to focus on.

Pat Tuer: There is a lot of variability between region to region and hospital to hospital in terms of capture of the VA population. So that is something our operators have done a great job with and continue to focus on. You did not ask about this, but as I think about 2027, one of the things that I think deserves to be called out is the success that we have had in the MA admit and appeal strategy, and how we are thinking about expanding that.

Speaker #6: You didn't ask about this, but as I think about 2027, one of the things that I think deserves to be called out is the success that we've had in the MA Admit and Appeal Strategy.

Speaker #6: And how we're thinking about expanding that. So, so far, relatively small insights. We've had 294 claims go through. Eighty-seven percent of those have been overturned in our favor.

Pat Tuer: So far, relatively small in size. We have had 294 claims go through. 87% of those have been overturned in our favor. 81% are being overturned before they go to the ALJ. A lot to like there. If we think about discharge growth in that population, the MA growth in those nine markets for MA was 36%. We have talked about how that has endeared us to the referral sources. They also saw total growth of about 9.5% with another benefit of 6.6% growth in Medicare. We have just completed educating all of our hospitals on expanding that pilot across every hospital, every payer for stroke, specifically. We have increased the number of total pilot hospitals from nine to 13 as well. I think we will start to see that incrementally tick up in Q4 and certainly in 2027, and then we will evaluate how this goes.

Speaker #6: 81% being overturned before they go to the ALJ. So a lot to like there. And if we think about discharge growth in that population, the MA growth in those nine markets for MA was 36%.

Speaker #6: And then we've talked about how that has endeared us to the referral sources. They also saw total growth of about 9.5%, with another benefit of 6.6% growth in Medicare.

Pat Tuer: They also saw total growth of about 9.5% with another benefit of 6.6% growth in Medicare. We have just completed educating all of our hospitals on expanding that pilot across every hospital, every payer for stroke, specifically. We have increased the number of total pilot hospitals from nine to 13 as well. I think we will start to see that incrementally tick up in Q4 and certainly in 2027, and then we will evaluate how this goes.

Speaker #6: So we have just completed educating all of our hospitals on expanding that pilot for across every hospital, every payer for stroke specifically. We've increased the number of total pilot hospitals from 9 to 13 as well.

Speaker #6: So I think we'll start to see that incrementally tick up in Q4 and certainly in 2027. And then we'll evaluate how this goes. The next two diagnoses that we would likely scale up through the organization is brain injury and spine, which we're having a lot of success with as well.

Pat Tuer: The next two diagnoses that we would likely scale up through the organization is brain injury and spine, which we are having a lot of success with as well. Just on the hiring and turnover front, turnover did tick up slightly in Q3 to 20.7%, but that remains below our historical levels. In the 10 years from 2014 to 2023, we averaged about 24.2%. Even if you back out the COVID years, the five years before COVID, 2015 to 2019, we averaged about 23.2%, so well below historical levels there. Hiring has continued to remain robust. We have more full-time net RN hires through three quarters of this year than we have had in the last five calendar years, on an individual basis. The high watermark there was in 2023.

Speaker #6: And then just on the hiring and turnover front, turnover did tick up slightly in Q3 to 20.7%, but that remains below our historical levels.

Speaker #6: In the 10 years from 2014 to 2023, we averaged about 24.2%. Even if you back out the COVID years, the five years before COVID—2015 to 2019—we averaged about 23.2%.

Pat Tuer: Even if you back out the COVID years, the five years before COVID, 2015 to 2019, we averaged about 23.2%, so well below historical levels there. Hiring has continued to remain robust. We have more full-time net RN hires through three quarters of this year than we have had in the last five calendar years, on an individual basis. The high watermark there was in 2023. Again, a lot of things to be optimistic about from a workforce perspective, as well as the other two buckets that I mentioned.

Speaker #6: So well below historical levels there. And hiring has continued to remain robust. We have more full-time net RN hires through three-quarters of this year.

Speaker #6: Then we've had in the last five calendar years, on an individual basis, the high watermark there in 2023. So again, a lot of things to be optimistic about from a workforce perspective.

Pat Tuer: Again, a lot of things to be optimistic about from a workforce perspective, as well as the other two buckets that I mentioned.

Speaker #6: As well as the other two buckets that I mentioned.

Operator: We will take our next question from Ann Hynes with Mizuho. Your line is open.

Speaker #1: We'll take our next question from Anne Hines with Mizuho. Your line is open.

Mark Tarr: Morning, Anne.

Pat Tuer: Hey, Anne.

Speaker #7: Good morning, Anne.

Ann Hynes: Good morning. Thank you. Just on the capacity thought, I know that your capacity is running very high, and I know about, I think you said like 35% of your hospitals may be running at 85% capacity. Can you update that stat for us? When do you think those capacity constraints could be freed to really accelerate same store discharge growth? Thanks.

Speaker #8: Hey, Anne.

Speaker #9: Good morning. Thank you. So just on the capacity thought, I know that your capacity is running very high and I know about I think you said like 35% of your hospitals may be running at 85% capacity.

Speaker #9: Can you update that stats for us? And when do you think those capacity constraints could be freed to really accelerate same-store discharge growth? Thanks.

Doug Coltharp: Yeah. It is a factor. It is not the only factor. Generally speaking, when you are running at high system wide occupancy rates, that is a really high class problem. Specifically, we called out a cohort of hospitals that have been running at greater than 90% capacity with an average occupancy of 95%. In Q1, we identified that there were 65 hospitals in that cohort. In Q2, the number dropped to 60, and in Q3, the number dropped further to 58. Across those three quarters, there have been 49 hospitals that have been present in that cohort for each of those three quarters. 19 of those will have bed additions between now and the end of fiscal year 2027, so that will help greatly in that regard. As Mark mentioned earlier, we are excited about the addition of these small format hospitals.

Speaker #7: Yeah, so it is a factor. It's not the only factor. And generally speaking, when you're running at high system-wide occupancy rates, that's a really high-class problem.

Speaker #7: Specifically, we called out a cohort of hospitals that have been running at greater than 90% capacity with an average capacity an average occupancy of 95%.

Speaker #7: And so in Q1, we identified that there were 65 hospitals in that cohort. In Q2, the number dropped to 60. And in Q3, the number dropped further to 58.

Doug Coltharp: In Q2, the number dropped to 60, and in Q3, the number dropped further to 58. Across those three quarters, there have been 49 hospitals that have been present in that cohort for each of those three quarters. 19 of those will have bed additions between now and the end of fiscal year 2027, so that will help greatly in that regard. As Mark mentioned earlier, we are excited about the addition of these small format hospitals. It's really going to help us address those in some markets where there are physical limitations on our ability to expand.

Speaker #7: Across those three quarters, there have been 49 hospitals that have been present in that cohort for each of those three quarters. 19 of those will have bed additions between now and the end of fiscal year 2027.

Speaker #7: So that'll help greatly in that regard. And as Mark mentioned earlier, we're excited about the addition of these small format hospitals. It's really going to help us address those in some markets where there are physical limitations on our ability to expand.

Doug Coltharp: It's really going to help us address those in some markets where there are physical limitations on our ability to expand.

Pat Tuer: Anne, this is Pat. In addition to what Doug has shared, and what Mark has mentioned as well, we're really excited about our development pipeline. Both our development team, our operators, and others at the home office have done a lot of work thinking about capacity expansions and how do we continue to take advantage of the demographic tailwind that is in front of us. Our pipeline from a de novo and small format hospital perspective is larger than it's ever been. We're working hard to figure out how do we guide the 6 to 10 hospitals a year with inclusive of North Carolina. We think we can get to the top of that range and potentially in the outer years, be above that range. We're working towards that and really excited about the pipeline, both from a de novo and small format perspective.

Pat Tuer: Ann, this is Pat. In addition to what Doug has shared, and what Mark has mentioned as well, we're really excited about our development pipeline. Both our development team, our operators, and others at the home office have done a lot of work thinking about capacity expansions and how do we continue to take advantage of the demographic tailwind that is in front of us.

Speaker #5: And this is Pat, just in addition to what Doug has shared, and what Mark has mentioned as well. We're really excited about our development pipeline.

Speaker #5: Both our development team, our operators, and others at the home office have done a lot of work thinking about capacity expansions and how do we continue to take advantage of the demographic tailwind that is in front of us.

Speaker #5: And our pipeline from a de novo and small format hospital perspective is larger than it's ever been. And we're working hard to figure out how do we we guide the 6 to 10 hospitals a year with inclusive of North Carolina.

Pat Tuer: Our pipeline from a de novo and small format hospital perspective is larger than it's ever been. We're working hard to figure out how do we guide the 6 to 10 hospitals a year with inclusive of North Carolina. We think we can get to the top of that range and potentially in the outer years, be above that range. We're working towards that and really excited about the pipeline, both from a de novo and small format perspective.

Speaker #5: We think we can get to the top of that range and potentially in the outer years be above that range. So we're working towards that and really excited about the pipeline both from a de novo and small format perspective.

Doug Coltharp: The demand is there to support it. If you look just at the counties in which Encompass Health has a presence, from September 2025 to 2026, in those counties, there were almost a half a million more Medicare beneficiaries, and roughly 50% of those, a little bit more than 50%, were fee-for-service versus Medicare Advantage. You've got an underserved population that continues to grow, and I know you've heard the mantra from us frequently, but the demographic tailwinds are still very much there.

Speaker #7: You know, and the demand is there to support it. If you look just at the counties in which Encompass Health has a presence, from September of 2025 to 2026, in those counties, there were almost a half a million more Medicare beneficiaries.

Speaker #7: And roughly 50% of those a little bit more than 50% were fee-for-service versus Medicare Advantage. So you've got an underserved population that continues to grow and it's I know you've heard the mantra from us frequently, but the demographic tailwinds are still very much there.

Ann Hynes: Great. Thank you so much.

Speaker #9: Great. Thank you so much.

Operator: We'll take our next question from Andrew Mok with Barclays. Your line is open.

Speaker #1: Well, take our next question from Andrew Mock with Barclays. Your line is open.

Doug Coltharp: Hey, good morning, Andrew.

Speaker #7: Hey, good morning, Andrew.

Andrew Mok: Hi. Good morning. Just wanted to follow up on the managed care pricing. The guidance assumption increased 125 basis points at the midpoint to a new range of 3.5% to 4%. Would love to hear what's driving that increase. Is the admit and appeal strategy part of that? Can you also confirm that that's unit pricing only and does not include shifts in acuity? Thanks.

Speaker #10: Hi, good morning. Just wanted to follow up on the managed care pricing. The guidance assumption increased 125 basis points at the midpoint to a new range of 3.5 to 4%.

Speaker #10: We'd love to hear what's driving that increase. Is the admit and appeal strategy part of that? And can you also confirm that that's unit pricing only and does not include shifts in acuity?

Speaker #10: Thanks.

Doug Coltharp: It does include shift in acuity, and it's benefiting from that. The biggest driver there is something that Pat mentioned before, which is, in that category, we include our VA CCN volume, and that's been growing consistently at north of 20%. As a reminder, that pays at the fee-for-service rate. The reason that we adjusted it up for the full year is because of the favorable performance we've had for the first three quarters of the year. Medicare Advantage is not included in that bucket. Again, that has skewed upward in acuity, in part because of the more stringent pre-authorization that we've been facing, and the fact that we've been able to replace some of the lower volume, some of the lower acuity patients there with the higher acuity, specifically the stroke example that Pat gave earlier.

Speaker #7: It does include shift in acuity, and it's benefiting from that. The biggest driver there is something that Pat mentioned before, which is that in that category, we include our VACCN volume, and that's been growing consistently at north of 20%.

Speaker #7: And as a reminder, that pays at the fee-for-service rate. So the reason that we adjusted it up for the full year is because of the favorable performance we've had for the first three quarters of the year.

Doug Coltharp: Medicare Advantage is not included in that bucket. Again, that has skewed upward in acuity, in part because of the more stringent pre-authorization that we've been facing, and the fact that we've been able to replace some of the lower volume, some of the lower acuity patients there with the higher acuity, specifically the stroke example that Pat gave earlier.

Speaker #7: Medicare Advantage is not included in that bucket. And again, that has skewed upward in acuity in part because of the more stringent pre-authorization that we've been facing.

Speaker #7: And the fact that we've been able to replace some of the lower volume some of the lower acuity patients there with the higher acuity.

Speaker #7: Specifically, the stroke example that Pat gave earlier.

Andrew Mok: Got it. Okay. That's helpful. Then maybe just a follow-up on the small-format hospitals. You mentioned that you have 2 in the pipeline, but I believe only 1 is expected to open in 2027. Can you confirm that 1 is still the expectation? Just given the smaller format and presumably faster speed to open, why isn't that a bigger number in 2027? Why can't you accelerate that? Thanks.

Speaker #10: Got it. Okay, that's helpful. And then maybe just a follow-up on the small-format hospitals. You mentioned that you have two in the pipeline, but I believe only one is expected to open in 2027.

Speaker #10: Can you confirm that one is still the expectation and just given the smaller format and presumably faster speed to open, why isn't that a bigger number in 2027?

Speaker #10: Why can't you accelerate that? Thanks.

Doug Coltharp: I can confirm that our expectation is that 1 will open in late 2027. The best explanation I can give you on why we're not moving faster right now is that small-format hospitals are not only new to us, they're new to the communities in which we're introducing those, which have their own licensing and permitting aspects to them. In some of those instances, the small-format hospital doesn't fit neatly within the definition of either an acute care hospital or more of a subsidiary type of arrangement. We're having to spend a little bit more time on the front end through the permitting and licensing processes so that there's a greater understanding of what requirements really need to be contained within the remote location versus those that are provided by the host location.

Speaker #7: So I can confirm that our expectation is that one will open in late '27. The best explanation I can give you on why we're not moving faster right now is that small format hospitals are not only new to us, they're new to the communities in which we're introducing those, which have their own licensing and permitting aspects to them.

Doug Coltharp: In some of those instances, the small-format hospital doesn't fit neatly within the definition of either an acute care hospital or more of a subsidiary type of arrangement. We're having to spend a little bit more time on the front end through the permitting and licensing processes so that there's a greater understanding of what requirements really need to be contained within the remote location versus those that are provided by the host location.

Speaker #7: And so in some of those instances, it doesn't fit the small format hospital doesn't fit neatly within the definition of either an acute care hospital or more of a subsidiary type of arrangement.

Speaker #7: And so we're having to spend a little bit more time on the front end, through the permitting and licensing processes, so that there's a greater understanding of what requirements really need to be contained within the remote location versus those that are provided by the host location.

Doug Coltharp: I think the good news is, really on a state-by-state basis, once you have cracked the code the initial time, the template is set, and we'll be able to go much faster. It's that aspect of it that gives us a lot of confidence that as we get rolling here, we're going to be able to accelerate that pipeline pretty significantly into 2028 and 2029. The design is there. We're confident in the design. We've got the capacity with our general contractors, and there's no capital constraint either.

Speaker #7: I think the good news is really on a state-by-state basis, once you have cracked the code, the initial time, the template is set and we'll be able to go much faster and it's that aspect of it that gives us a lot of confidence that as we get rolling here, we're going to be able to accelerate that pipeline pretty significantly into 2028 and 2029.

Speaker #7: The design is there. We're confident in the design. We've got the capacity with our general contractors and there's no capital constraint either.

Pat Tuer: I would add to that just from a market identification standpoint, our operators and development team have identified about 200 locations where this potentially could happen. As Doug mentioned, we really think that we're going to be in a position to ramp this up in 2028 and 2029. I think we would all be collectively disappointed if we're opening less than 6 of those a year by that point.

Speaker #5: I would add to that that just from a market identification standpoint, our operators and development team have identified about 200 locations where this potentially could happen.

Speaker #5: As Doug mentioned, we really think that we're going to be in a position to ramp this up in 2028 and 2029. I think we would all be collectively disappointed if we're opening less than six of those.

Speaker #5: A year by that point.

Operator: We'll take our next question from Matthew Gillmor with KeyBanc. Your line is open.

Speaker #1: We'll take our next question from Matthew Gilmore with KeyBank. Your line is open.

Doug Coltharp: Morning, Matt.

Speaker #7: Good morning, Matt. Hello, Matt.

Pat Tuer: Hello, Matt.

Matthew Gillmor: Hey, good morning, everyone. I wanted to ask about the RCD expansion. I think you indicated 75 more hospitals will be subject to RCD in 2027. At least when we look at the CMS reports, it seemed like the affirmation rate with Palmetto had been improving. Just wanted to see if you had any comments in terms of what to expect as that gets rolled out to additional hospitals next year.

Speaker #8: Hey, good morning, everyone. I wanted to ask about the RCD expansion. I think you indicated 75 more hospitals will be subject to RCD in 2027.

Speaker #8: And at least when we look at the CMS reports, it seemed like the affirmation rate with Palmetto had been improving. Just wanted to see if you had any comments in terms of what to expect as that gets rolled out to additional hospitals next year.

Doug Coltharp: Yeah. I will start by saying that with regard to the expansion into Jurisdiction JJ, which does include 75 more of our hospitals, we are having ongoing discussions with both Palmetto and CMS to understand specifically how it is going to work. Our greatest concern is whether or not Palmetto is going to be able to handle this administratively. Palmetto's involvement in RCD thus far has been limited to the state of Alabama, and seven of our hospitals are included there. But the expansion into Jurisdiction JJ is going to increase the volume that they are going to have to process by more than 10 times. It is a requirement that during cycle 1, which is slated to begin on 1 January and extend through 30 June, all providers will be on 100% prepayment claim review. There is no option out of that in cycle 1.

Speaker #7: Yeah. So I'll start by saying that with regard to the expansion into jurisdiction JJ, which does include 75 more of our hospitals, we are having ongoing discussions with both Palmetto and CMS to understand specifically how it's going to work.

Speaker #7: Our greatest concern is whether or not Palmetto is going to be able to hand this administratively Palmetto's involvement in RCD thus far has been limited to the state of Alabama.

Doug Coltharp: Palmetto's involvement in RCD thus far has been limited to the state of Alabama, and seven of our hospitals are included there. But the expansion into Jurisdiction JJ is going to increase the volume that they are going to have to process by more than 10 times. It is a requirement that during cycle 1, which is slated to begin on 1 January and extend through 30 June, all providers will be on 100% prepayment claim review. There is no option out of that in cycle 1.

Speaker #7: And seven of our hospitals are included there. But the expansion into jurisdiction JJ is going to increase the volume that they're going to have to process by more than 10 times.

Speaker #7: It's a requirement that during cycle one, which will is slated to begin on January 1st and extend through June 30th, all providers will be on 100% prepayment claim review.

Speaker #7: There's no option out of that in cycle one. So that's going to be a real burden on Palmetto and we just want a greater understanding as to how they're going to be able to process that.

Doug Coltharp: That is going to be a real burden on Palmetto, and we just want a greater understanding as to how they are going to be able to process that. That said, to the extent that we progress through cycle 1 and hospitals exceed the target affirmation rate of 80%, which we would have a high degree of confidence based on our experience to date, they will then beginning 1 July, one of the options we would have is to move from the 100% prepayment claim review to a 5% spot check. We have just moved into cycle 2 for the 24 hospitals that we have in Texas, where we performed very well and above the target affirmation rate, and we have made the decision to move to the 5% spot check there.

Speaker #7: That said, to the extent that we progress through cycle one, and the hospitals exceed the target affirmation rate, of 80%, which we would have a high degree of confidence based on our experience to date, they will.

Speaker #7: Then beginning July 1st, one of the options we would have is to move from the 100% prepayment claim review to a 5% spot check.

Doug Coltharp: We have just moved into cycle 2 for the 24 hospitals that we have in Texas, where we performed very well and above the target affirmation rate, and we have made the decision to move to the 5% spot check there. I think it is our anticipation that we will avail ourselves of the same opportunity as it arises in other RCD markets.

Speaker #7: We have just moved into cycle two for the 24 hospitals that we have in Texas, where we performed very well and above the target affirmation rate.

Speaker #7: And we've made the decision to move to the 5% spot check there. And I think it's our anticipation that we'll avail ourselves of the same opportunity as it arises in other RCD markets.

Doug Coltharp: I think it is our anticipation that we will avail ourselves of the same opportunity as it arises in other RCD markets.

Matthew Gillmor: Great. That is helpful. Then maybe just one follow-up. On the bad debt expense, you called out some impact from, I think, a system conversion. I was just hoping you could explain what happened there.

Speaker #8: Great, that's helpful. And then maybe just one follow-up on the bad debt expense. You called out some impact from, I think, a system conversion.

Speaker #8: I was just hoping you could explain what happened there.

Doug Coltharp: Yeah. So really about two-thirds of the increase was due to the system conversion. I will probably give you more detail than you would want. But in Q2, we converted our patient billing system from a legacy system that was called PATCOM to the Oracle module. We did so because PATCOM was essentially being sunsetted, and the Oracle module has enhanced functionality as well as greater compatibility with our Fusion ERP. When we initiated the cut-over, the pending claims that were left in the legacy system required a more manual processing, and at the same time, we were shifting some of our resources in that area over to processing claims under the new system. As these claims were pending, they became subject to our aging-based reserve methodology.

Speaker #7: Yeah. So really about two-thirds of the increase was due to the system conversion. I'll probably give you more detail than you would want. But in Q2, we converted our patient billing system from a legacy system that was called PATCOM to the Oracle module.

Speaker #7: And we did so because PATCOM was essentially being sunsetted and the Oracle module has enhanced functionality as well as greater comparability with our Fusion ERP.

Doug Coltharp: When we initiated the cut-over, the pending claims that were left in the legacy system required a more manual processing, and at the same time, we were shifting some of our resources in that area over to processing claims under the new system. As these claims were pending, they became subject to our aging-based reserve methodology.

Speaker #7: When we initiated the cutover, the pending claims that were left in the legacy system required more manual processing. And at the same time, we were shifting some of our resources in that area over to processing claims under the new system.

Speaker #7: As these claims were pending, they became subject to our aging-based reserve methodology. By the end of Q3, we were essentially caught up on our Medicare billing and collections, but the Q had not been cleared out for our managed care and our Medicare Advantage.

Doug Coltharp: By the end of Q3, we were essentially caught up on our Medicare billing and collections, but the queue had not been cleared out for our managed care and our Medicare Advantage. Those payers typically run at a higher bad debt expense than Medicare fee for service, and they also generally require higher patient co-pays. We cannot bill for the co-pays until the payers process our claims, so it creates this backlog. Now, we expect that queue to be fully cleared by the end of the year. It is important to note that all claims since conversion are processing through the Oracle module without an issue. So this is really a one-time situation.

Speaker #7: And those payers typically run at a higher bad debt expense than Medicare fee for service. And they also generally require higher patient copays. And we can't bill for the copays until the payer's process our claim.

Doug Coltharp: We cannot bill for the co-pays until the payers process our claims, so it creates this backlog. Now, we expect that queue to be fully cleared by the end of the year. It is important to note that all claims since conversion are processing through the Oracle module without an issue. So this is really a one-time situation.

Speaker #7: So it creates this backlog. Now, we expect that Q to be fully cleared by the end of the year. And it is important to note that all claims since conversion are processing through the Oracle module without an issue.

Speaker #7: So this is really a one-time situation.

Operator: We will take our next question from Whit Mayo with Leerink. Your line is open.

Speaker #1: We'll take our next question from Whit Mayo with Leer Inc. Your line is open.

Doug Coltharp: Morning, Whit.

Pat Tuer: Morning, Whit.

Speaker #7: Good morning, Whit. Morning, Whit.

Morgan McCarthy: Hey, guys. Good morning. It is Morgan McCarthy on for Whit. Morning. Your unit cost per discharge were effectively flat on a year-over-year basis. Is there anything to call out, whether it is this year or in prior years, related to provider taxes or any other cost items that might skew that metric?

Speaker #9: Hey, guys. Good morning. It's Morgan McCarthy on for Whit. So your unit morning. So your unit cost per discharge were effectively flat on a year-over-year basis.

Speaker #9: Is there anything to call out, whether it's this year or in prior years, related to provider taxes or any other cost items that might skew that metric?

Doug Coltharp: The net impact from provider taxes was actually going to be a negative on that. But where we had some gains, SWB was very favorable. That was driven by lower group medical expense in the quarter, and also just by the lower overall turnover. EPOB was favorable for the quarter. Length of stay was favorable for the quarter. I will note that we had a benefit in supplies. You may recall that in Q3 2025, we called out the fact that we had advanced some purchases of supplies in advance of the Fusion conversion in order to avoid any disruption. Obviously, we did not have to replicate this year. But generally, when you have a pricing increase in the 4% range, the flow-through and the efficiency there tends to be high.

Speaker #7: Yeah. So the net impact from provider taxes was actually going to be a negative on that. But where we had some gains, again, SWB was very favorable.

Speaker #7: That was driven by lower group medical expense in the quarter. And then also just by the lower overall turnover. EPOB was favorable for the quarter.

Speaker #7: Length of stay was favorable for the quarter. I will note that we had a benefit in supplies. You may recall that in Q3 of '25, we called out the fact that we had advanced some purchases of supplies in advance of the Fusion conversion.

Doug Coltharp: You may recall that in Q3 2025, we called out the fact that we had advanced some purchases of supplies in advance of the Fusion conversion in order to avoid any disruption. Obviously, we did not have to replicate this year. But generally, when you have a pricing increase in the 4% range, the flow-through and the efficiency there tends to be high.

Speaker #7: In order to avoid any disruption. And obviously, we didn't have to replicate this year. But generally, when you've got a pricing increase in the 4% range, the flow through and the efficiency there tends to be high.

Morgan McCarthy: Thank you.

Speaker #9: Thank you.

Operator: And we'll take our next question from Ryan Langston with TD Cowen. Your line is open.

Speaker #1: And we'll take our next question from Ryan Langston with Kellan. Your line is open.

Doug Coltharp: Morning, Ryan.

Ryan Langston: Great. Thanks.

Speaker #7: Morning, Ryan.

Speaker #8: Great. Thanks. Hey, good morning, guys. I appreciate the questions. You had some really nice acuity pickup recently that's carried through into the third quarter.

Ryan Langston: Hey, good morning, guys. I appreciate the questions. You had some really nice acuity pickup recently that has carried through into Q3. I guess, is that acuity lift a durable opportunity into 2027, and might RCD expansion impact the acuity of the patient transfers from the acute care hospitals?

Speaker #8: I guess, is that acuity lift a durable opportunity into 2027? And might RCD expansion impact the acuity of the patient transfers from the acute care hospitals?

Pat Tuer: I will start there. Acuity or RICC mix can shift on a quarter-over-quarter basis. We do think that some of the trends that we are seeing are sustainable. We talked, last quarter, about the shift in acuity, and I will call out a couple of diagnosis categories where we saw some really nice growth that are driving that again. We had 9.3% growth in our neuro RICC, 5.1% growth in stroke, 5.7% in brain injury, and then major trauma was up 10.3%. Some of those had a softer comp last year, but even if you look at it on a 2-year stack from a same-store basis, brain injury was up 9.8%, neuro up 8.5%, stroke and major trauma up 5.7%. That mix is gaining because lower acuity conditions like lower extremity joint replacements are down. In Q3, same-store lower extremity joint replacements were down 5.3%.

Speaker #7: I'll start there and acuity can shift or rick mix can shift on a quarter over quarter basis, but we do think that some of the trends that we're seeing are sustainable.

Speaker #7: We talked last quarter about the shift in acuity and I'll call out a couple of diagnosis categories where we saw some really nice growth that are driving that again.

Pat Tuer: We had 9.3% growth in our neuro RICC, 5.1% growth in stroke, 5.7% in brain injury, and then major trauma was up 10.3%. Some of those had a softer comp last year, but even if you look at it on a 2-year stack from a same-store basis, brain injury was up 9.8%, neuro up 8.5%, stroke and major trauma up 5.7%. That mix is gaining because lower acuity conditions like lower extremity joint replacements are down. In Q3, same-store lower extremity joint replacements were down 5.3%.

Speaker #7: We had 9.3% growth in our neuro RIC, 5.1% growth in stroke, 5.7% in brain injury, and then major trauma was up 10.3%. Some of those had a softer comp last year, but even if you look at it on a two-year stack from a same store basis, brain injury was up 9.8%, neuro up 8.5%, stroke and major trauma up 5.7%.

Speaker #7: And that mix is gaining because lower acuity conditions, like lower extremity joint replacements, are down. So in Q3, same store lower extremity joint replacements were down 5.3% on a total store basis.

Pat Tuer: On a total store basis, they were down 0.7%, and we were able to backfill that volume with those higher acuity conditions. Not only are we seeing an increase from a RICC perspective, the percent of patients that come to us with comorbid conditions, it also continues to increase. Then we are getting the benefit on the pricing side as well from the outcomes that we are seeing. Even though we are seeing higher acuity conditions, we continue to do a better job of getting those patients home, and that has a favorable pickup on the pricing line.

Speaker #7: They were down 0.7%. And we were able to backfill that volume with those higher acuity conditions. Not only are we seeing an increase in from a RIC perspective, the percent of patients that come to us with comorbid conditions also continues to increase.

Speaker #7: And then we're getting the benefit on the pricing side as well from the outcomes that we're seeing. So even though we're seeing higher acuity conditions, we continue to do a better job of getting those patients home.

Speaker #7: And that has a favorable pickup on the pricing line. We don't anticipate that RCD expansion will have any impact on patient acuity. We believe we are admitting appropriate patients and providing the appropriate documentation for those patients.

Doug Coltharp: We do not anticipate that RCD expansion will have any impact on patient acuity. We believe we are admitting IRF-appropriate patients and providing the appropriate documentation for those patients.

Ryan Langston: Got it. Sorry if I missed this in the supplemental payment commentary, but is there any update on the potential tax waiver program in Florida? Can you remind us if there is any impact, plus or minus, to guidance for 2026? Thank you.

Speaker #8: Got it. And then sorry if I missed this in the supplemental payment commentary, but is there any update on the potential tax waiver program in Florida?

Speaker #8: And can you remind us if there's any impact plus or minus to guidance for 2026? Thank you.

Doug Coltharp: Yeah. We went through the fact that we reversed the year-to-date accrual through the first three quarters. That is because the fiscal year 2026 ended on 1 October for Florida without a decision, positive or negative, from CMS on the proposal set forth by Florida. The proposal set forth would include waivers for many of our hospitals in that state. If that were to come through in Q4, it has a potential favorable increase to EBITDA of about $8 million, which would be the sum of the roughly $5.5 million net impact that we reversed in our Q3 earnings, plus the pickup we would get for Q4. As we look into 2027, again, if it is approved with the waivers in it as submitted, that would be a positive.

Speaker #7: Yeah. So we went through the fact that we reversed the year-to-date accrual through the first three quarters. And that is because the fiscal year '26 ended on October 1st for Florida without a decision, positive or negative, from CMS on the proposal set forth by Florida.

Speaker #7: The proposal set forth would include waivers for many of our hospitals in that state. If that were to come through in the fourth quarter, it has the potential favorable increase to EBITDA of about $8 million.

Doug Coltharp: If that were to come through in Q4, it has a potential favorable increase to EBITDA of about $8 million, which would be the sum of the roughly $5.5 million net impact that we reversed in our Q3 earnings, plus the pickup we would get for Q4. As we look into 2027, again, if it is approved with the waivers in it as submitted, that would be a positive. Again, on a year-over-year basis, we took that $11.5 million hit related to the fiscal year 2025 Florida plan in Q2, and we are not anticipating that we would replicate that.

Speaker #7: Which would be the sum of the roughly $5.5 million net impact that we reversed in our Q3 earnings plus the pickup we would get for Q4.

Speaker #7: As we look into 2027, again, if it's approved with the waivers in it as submitted, that would be a positive and again, on a year-over-year basis, we took that 11.5 million hit related to the fiscal year '25 Florida plan in the second quarter and we're not anticipating that we would replicate that.

Doug Coltharp: Again, on a year-over-year basis, we took that $11.5 million hit related to the fiscal year 2025 Florida plan in Q2, and we are not anticipating that we would replicate that.

Operator: We will move next to Joanna Gajuk with Bank of America. Your line is open.

Speaker #1: We'll move next to Joanna Gajuk with Bank of America. Your line is open.

Doug Coltharp: Morning, Joanna.

Joanna Gajuk: Oh, hi. Good morning. Thanks so much for taking the question. I guess first on the small format hospital, it is a very exciting type of development there. Can you remind us, I could not remember whether you talk about the returns on these projects versus, say, your typical 40, 50-bed hospital, because I guess you are leveraging some of the local costs in there, right? Can you remind us how that progresses, I guess, when you have a small format versus just a regular hospital in terms of return?

Speaker #7: Good morning, Joanna.

Speaker #9: Oh, hi. Good morning. Thanks. Hey, good morning. Thanks so much for taking that question. So I guess first on the small format hospitals, it was very exciting.

Speaker #9: I guess type of development there. But can you remind us? I couldn't remember whether you talk about the returns on these projects. Versus say, your typical 40, 50-bed hospital.

Speaker #9: Because I guess you're leveraging some of the local costs in there, right? So can you remind us how that progresses, I guess, when you have a small format versus just a regular hospital?

Speaker #9: Because of returns.

Speaker #7: Yeah. Yeah, absolutely. So we have been excuse me. We've been targeting in realizing returns. IRRs on our de novo program in the mid-teens. And that's based on maintaining a cost per bed, which we feel some degree of confidence in moving forward of roughly 1.25 million dollars per bed.

Doug Coltharp: Yeah, absolutely. We have been targeting and realizing returns, IRRs, on our de novo program in the mid-teens, and that is based on maintaining a cost per bed, which we feel some degree of confidence in moving forward of roughly $1.25 million per bed. Bed expansions to existing hospitals offer the greatest leverage opportunity and then also the highest returns. We are at 25% or higher with regard to the IRR on bed expansions at existing hospitals, and the average cost per bed there tends to be right around $850,000. The small format hospitals are going to fall right in between. We are estimating the cost per bed on those will be right at $1 million, and we are targeting an IRR of about 20%. You identified the ability to get some efficiencies by sharing certain components of the administrative staff with the host hospital.

Speaker #7: Bed expansions to existing hospitals offer the greatest leverage opportunity and then also the highest returns. We are at 25% or higher with regard to the IRR on bed expansions at existing hospitals.

Doug Coltharp: We are at 25% or higher with regard to the IRR on bed expansions at existing hospitals, and the average cost per bed there tends to be right around $850,000. The small format hospitals are going to fall right in between. We are estimating the cost per bed on those will be right at $1 million, and we are targeting an IRR of about 20%. You identified the ability to get some efficiencies by sharing certain components of the administrative staff with the host hospital.

Speaker #7: And the average cost per bed there tends to be right around $850,000. The small format hospitals are going to fall right in between. We're estimating the cost per bed on those will be right at a million dollars.

Speaker #7: And we're targeting an IRR of about 20%. You identified the ability to get some efficiencies by sharing certain components of the administrative staff with the host hospital.

Doug Coltharp: As a result, whereas we run on a corporate-wide basis, an EPOB, of just under 3.4 times, we think there is an opportunity for the small format hospitals to have an EPOB below 3 times, and that is a highly sensitive metric with regard to the P&L and therefore the flow-through to returns.

Speaker #7: And as a result, whereas we run on a corporate-wide basis and EPOB of just under 3.4 times, we think there's an opportunity for the small format hospitals to have an EPOB below three times.

Speaker #7: And that's a highly sensitive metric with regard to the P&L and therefore the flow-through to returns.

Joanna Gajuk: Okay. Yeah, this is great. Thank you for that. I guess, the other question that I had in terms of this acuity-driven pricing, it seems like it is very sustainable there, and thanks for breaking out the volume group by the different categories. Anything to call out that would suggest that somehow things could slow down even next year? I know it is 12, so quarter to quarter, but if we think, say, next 12 months or so, anything that would say, "Hey, things should slow down," or change versus your trajectory. Thank you.

Speaker #9: Okay. Yeah, this is great. Thank you for that. And I guess the other question that I had in terms of this acuity, driven pricing, seems like a very sustainable there.

Speaker #9: And thanks for breaking out the volume group. I did different categories. So, anything to collaborate that would suggest somehow things could slow down in the next year?

Speaker #9: I know it's 12, though, quarter to quarter. But if we think, say, the next 12 months or so, anything that would say, hey, things should slow down or change versus your trajectory.

Speaker #9: Thank you.

Doug Coltharp: Other than to recall that at least some of the increase in acuity that is flowing through in the pricing growth is attributable to the trends that we have been seeing within Medicare Advantage. The increase in pre-authorization denials that skewed us towards a higher acuity within our MA book of business first became really prevalent in Q4 2025. If you looked at Q4 2025, we had 4.1% net revenue per discharge. Our MA discount for that quarter, it tends to widen out from Q3 to Q4 because MA price increases on a calendar basis and fee-for-service increases on a fiscal year basis was 2%. As we anniversary those higher increases, even if acuity is maintained at the current levels, the year-over-year pricing change is going to be less pronounced.

Speaker #7: Other than to recall that at least some of the increase in acuity that's flowing through in the pricing growth is attributable to the trends that we've been seeing within Medicare Advantage.

Speaker #7: And the increase in pre-authorization denials that skewed us towards a higher acuity within our MA book of business first became really prevalent in Q4 of '25.

Doug Coltharp: If you looked at Q4 2025, we had 4.1% net revenue per discharge. Our MA discount for that quarter, it tends to widen out from Q3 to Q4 because MA price increases on a calendar basis and fee-for-service increases on a fiscal year basis was 2%. As we anniversary those higher increases, even if acuity is maintained at the current levels, the year-over-year pricing change is going to be less pronounced.

Speaker #7: So if you looked at Q4 of '25, we had a 4.1% net revenue per discharge. Our MA discount for that quarter, it tends to widen out from Q3 to Q4 because MA price increases on a calendar basis and fee-for-service increases on a fiscal year basis was 2%.

Speaker #7: And so, as we anniversary those higher increases, even if acuity is maintained at the current levels, the year-over-year pricing change is going to be less pronounced.

Operator: We will take our next question from Brian Tanquilut with Jefferies. Your line is open.

Speaker #1: We'll take our next question from Brian Tinkelet with Jefferies. Your line is open.

Brian Tanquilut: Hey, good morning, guys.

Speaker #8: Hey, good morning, guys. Good morning. Congratulations. Good morning. Yeah. So maybe Doug, my first question, contract FTE this quarter showed some pretty good improvement.

Pat Tuer: Good morning.

Pat Tuer: Good morning. Congrats on the quarter.

Pat Tuer: Congrats on the quarter.

Brian Tanquilut: Good morning. Yeah. Doug, my first question. Your contract FTE this quarter showed some pretty good improvement, and I know in Q2 you said that the gains were getting smaller. Just curious what you are seeing there in terms of on the permanent side, hiring, retention, and the career ladder grads that you are putting out there, and how that is translating into contract labor.

Speaker #8: And I know in Q2 you said that the gains were getting smaller. So just curious what you're seeing there in terms of on the permanent side hiring, retention, and the career ladder grads that you're putting out there.

Speaker #8: And how that's translating into contract labor.

Doug Coltharp: Yeah, I am going to toss that one over to Pat because it is something that he spends a lot of time focused on.

Speaker #7: Yeah, I'm going to toss that one over to Pat, because it's something that he spends a lot of time focused on.

Pat Tuer: Yeah, Doug continues to challenge us on the operations side by talking about the diminished returns that we are going to see in reducing contract labor and premium pay, and there is a truth to that. But this was another really strong quarter, and I highlighted some of the hiring and turnover dynamics earlier in the call. But we still have, if you look at contract labor, extra shifts, sign-on, overtime, and you normalize that by a per patient day basis, we still have a couple dozen hospitals that are over $100 per patient day in spend. So there still is juice for us to squeeze there, and we have had a lot of success working on those higher spend hospitals to bring that number down. Again, just to reinforce what I said earlier, net RN hires and therapy hires has not been better in years.

Speaker #3: Yeah. And Doug continues to challenge us on the operation side by talking about the diminished returns that we're going to see in reducing contract labor and premium pay.

Speaker #3: And there is a truth to that. But this was another really strong quarter. And I highlighted some of the hiring and turnover dynamics earlier in the call.

Pat Tuer: But we still have, if you look at contract labor, extra shifts, sign-on, overtime, and you normalize that by a per patient day basis, we still have a couple dozen hospitals that are over $100 per patient day in spend. So there still is juice for us to squeeze there, and we have had a lot of success working on those higher spend hospitals to bring that number down. Again, just to reinforce what I said earlier, net RN hires and therapy hires has not been better in years.

Speaker #3: But we still have, if you look at contract labor, extra shifts, sign-on, overtime, and you normalize that by a per-patient day basis, we still have a couple of dozen hospitals that are over $100 per patient day in spend.

Speaker #3: So there still is juice for us to squeeze there. And we've had a lot of success working on those higher spend hospitals to bring that number down.

Speaker #3: Again, just to reinforce what I said earlier, net RN hires. And therapy hires has not been better in years. Even if turnover ticked up a bit, the hiring dynamics have certainly overcame that.

Pat Tuer: Even if turnover ticked up a bit, the hiring dynamics have certainly overcame that, and turnover on a historical basis is still very strong. From a ladder perspective, we are up to 55% of eligible nurses are on the ladder. That represents about 31% of all of our full-time nurses being on the ladder. They have to be here for a certain period of time to move up into the ladder. So there is some upside there. Again, we had a big bolus in 2026 of the ladder, and we are going to anniversary some of that, so any of that upside within the ladder, we will be able to take those dollars and not be as pronounced as they were in 2026. But our largest bucket of opportunity is non-certified, non-laddered nurses, which represents about 60% of our full-time nurses.

Speaker #3: And turnover on a historical basis is still very strong. From a ladder perspective, we are up to 55% of eligible nurses who are on the ladder.

Speaker #3: That represents about 31% of all of our full-time nurses being on the ladder. They have to be here for a certain period of time, to move up into the ladder.

Pat Tuer: So there is some upside there. Again, we had a big bolus in 2026 of the ladder, and we are going to anniversary some of that, so any of that upside within the ladder, we will be able to take those dollars and not be as pronounced as they were in 2026. But our largest bucket of opportunity is non-certified, non-laddered nurses, which represents about 60% of our full-time nurses.

Speaker #3: So there's some upside there. Again, we had a big bolus in 2026 of the ladder. And we're going to anniversary some of that. So any of that upside within the ladder will be able to take those dollars and not be as pronounced as they were in 2026.

Speaker #3: But our largest bucket of opportunity is non-certified, non-laddered nurses, which represents about 60% of our full-time nurses. And again, we have some variation from region to region that we're working to improve upon.

Pat Tuer: Again, we have some variation from region to region that we are working to improve upon. I think if we can continue to do that, we are going to continue to see improvements, not only in turnover reduction in the premium pay buckets, but also in the continued sustainability of the higher acuity patients that we have been able to bring in.

Speaker #3: And I think if we can continue to do that, we're going to continue to see improvements not only in turnover reduction in the premium pay buckets, but also in the continued sustainability of the higher acuity patients that we've been able to bring in.

Mark Tarr: Brian, you have heard us say before, relative to contract labor, we have given our operators the green light. If they have got the volume and need to have contract labor to accommodate that volume, they need to go ahead, and we will take the hit on a short term until we can work it back out of the system. But we are not being throttled on our volume because of the focus on eliminating contract labor.

Speaker #2: Brian, you first say before, relative to contract labor, we've given our operators the green light. If they've got the volumes and need to have contract labor to accommodate that volume, they need to go ahead.

Speaker #2: And we'll take the hit on a short term until we can work it back out of the system. But we are not being throttled on our volume because of the focus on eliminating contract labor.

Brian Tanquilut: Maybe my follow-up, just as I think about the hospitals that you have opened in the H1 of the year, how are they tracking in terms of hitting breakeven or your typical ramp? Just curious how this class of new openings are performing. Thank you.

Speaker #8: Maybe my follow-up, just as I think about the hospitals that you've opened in the first half of the year, how are they tracking in terms of hitting break even in your typical ramp?

Speaker #8: I mean, just curious how this class of new openings are performing. Thank you.

Doug Coltharp: Yeah. So remember, we are heavily skewed towards the back end of the year, with four hospitals, four of the eight opening up in Q4. That said, we think that these are tracking in accordance with our recent historical performance. Just as a reminder there, generally what we have been seeing is that our de novo hospitals were achieving a four-wall positive EBITDA by about month 6, and they are climbing over a 70% occupancy by about month 10. Then they are achieving what we would suggest is full maturity and typically qualifying for a bed addition sometime between year 3 and year 4. So we have no reason to expect that the performance of the current class is going to be any different from that recent historical.

Speaker #7: Yeah. So remember, we're heavily skewed towards the back end of the year, with four hospitals, four of the eight opening up in Q4. That said, we think that these are tracking in accordance with our recent historical performance.

Speaker #7: And just as a reminder there, generally what we have been seeing is that our de novo hospitals are achieving four-wall positive EBITDA by about month six.

Speaker #7: And they're climbing over a 70% occupancy by about month 10th. And then they're achieving what we would suggest is full maturity and typically qualifying for a bed addition, sometime between year three and year four.

Doug Coltharp: Then they are achieving what we would suggest is full maturity and typically qualifying for a bed addition sometime between year 3 and year 4. So we have no reason to expect that the performance of the current class is going to be any different from that recent historical.

Speaker #7: So we have no reason to expect that the performance of the current class is going to be any different from that recent historical.

Operator: We will take our next question from AJ Rice with UBS. Your line is open.

Speaker #1: We'll take our next question from AJ Rice with UBS. Your line is open.

Mark Tarr: Good morning, AJ.

Speaker #5: Well, thanks for hiring me. Yeah. First question, on the discharge growth on the same-store base, there's been a lot of focus on that. I wondered if you would just offer us any comments.

AJ Rice: Thanks. Hi, everybody.

AJ Rice: Yeah. First question, on the discharge growth on the same store base, there's been a lot of focus on that. I wondered if you would just offer us any comments. I think you mentioned that you had the final four closures will anniversary in February of those, and you've obviously had the pacing on the new facilities. Anything to call out in the way to think about same store discharge growth over the next number of quarters, year, where there's any challenges or where there's some easy comps? I know you got a long-term target of 4% to 6% growth on that.

Speaker #5: I think you mentioned that you had the final four closures will anniversary in February. Of those, and then you've obviously had the pacing on the new facilities.

Speaker #5: Anything to call out in the way to think about same-store discharge growth over the next number of quarters, year, where there's any challenges or where there's some easy comps?

Speaker #5: I know you got a long-term target of four to 6% growth on that.

Doug Coltharp: Well, actually, I think our total discharge growth from 2023 to 2027, the target that we put out there was 6% to 8%. We didn't break that down between new store and same store. This won't surprise you, AJ, but I'm going to start with my usual disclaimer that we think it is increasingly less relevant to think about the distinction between new store and same store, that what really matters most is total discharge growth and the capital that's required to generate it. Having now said my piece with regard to the disclaimer, I'm going to take you through five factors that we think are relevant to looking at same store. The first that you mentioned was the impact from the four-unit consolidations. That impact, on a net basis, we estimate for Q3, was about 40 basis points.

Speaker #7: Yeah, so actually, I think our total discharge growth from 2023 to 2027, the target that we put out there, was 6% to 8%.

Speaker #7: We didn't break that down between new-store and same-store. This won't surprise you, AJ, but I'm going to start with my usual disclaimer that we think it is increasingly less relevant to think about the distinction between new-store and same-store. What really matters most is total discharge growth and the capital that's required to generate it.

Doug Coltharp: Having now said my piece with regard to the disclaimer, I'm going to take you through five factors that we think are relevant to looking at same store. The first that you mentioned was the impact from the four-unit consolidations. That impact, on a net basis, we estimate for Q3, was about 40 basis points.

Speaker #7: Having now said my piece with regard to the disclaimer, I'm going to take you through five factors that we think are relevant to looking at same-store.

Speaker #7: The first that you mentioned was the impact from the four-unit consolidations. That impact on a net basis, we estimate for Q3 was about 40 basis points.

Doug Coltharp: That's down from 70 basis points in Q2 and from 90 basis points in Q1, and that will be fully lapped in Q1 2027. As a reminder, the reduction in the volumes related to those unit closures carried no impact to EBITDA. The second is something that I mentioned earlier, which is that cohort of high occupancy hospitals.

Speaker #7: That's down from 70 basis points in Q2 and from 90 basis points in Q1. And that will be fully lapped in Q1, '27. And as a reminder, the reduction in the volumes related to those unit closures carried no impact to EBITDA.

Speaker #7: The second is something that I mentioned earlier, which is that cohort of high occupancy hospitals: 65 above 90% in Q1, 60 above 90% in Q2, 58 above 90% in Q3, 49 hospitals consistent through all three of those quarters, 19 of those will have bed additions coming on board prior to the end of the year in '27.

Doug Coltharp: 65% above 90% in Q1, 60% above 90% in Q2, 58% above 90% in Q3. 49 hospitals consistent through all three of those quarters. 19 of those will have bed additions coming on board prior to the end of the year in 2027. A third factor I would mention was the change that we saw in MA pre-authorization denials beginning in Q3, or excuse me, in Q4 of last year. If you look at total MA discharges in Q3, it actually declined 1.1%. Adjusted for the unit closures, which were disproportionately high in Medicare Advantage from a patient mix, especially the sole SNF unit that we closed, we would have been up 1%. Still not the height of our aspirations. As Pat mentioned earlier, in the nine admit and appeal pilot markets for the quarter, total discharge growth was up 9.3%.

Speaker #7: The third factor I would mention was the change that we saw in MA pre-authorization denials beginning in Q3 or, excuse me, in Q4 of last year.

Doug Coltharp: If you look at total MA discharges in Q3, it actually declined 1.1%. Adjusted for the unit closures, which were disproportionately high in Medicare Advantage from a patient mix, especially the sole SNF unit that we closed, we would have been up 1%. Still not the height of our aspirations. As Pat mentioned earlier, in the nine admit and appeal pilot markets for the quarter, total discharge growth was up 9.3%.

Speaker #7: If you look at total MA discharges in Q3, it actually declined 1.1%. Adjusted for the unit closures, which were disproportionately high in Medicare Advantage for the patient mix, especially the sole sniff unit that we closed, we would have been up 1%.

Speaker #7: Still not the height of our aspirations. As Pat mentioned earlier, in the nine admit-and-appeal pilot markets for the quarter, total discharge growth was up 9.3%.

Doug Coltharp: What we have demonstrated is that pilot is working. As Pat outlined, we are looking forward to extending that across stroke in all of our hospitals, and then bringing more hospitals into the fold from a pilot perspective. In terms of bed additions and new hospitals, as we mentioned previously, bed additions in 2026 were also heavily weighted towards the H2 of the year. Q3 benefited from only 54 beds added to existing hospitals in the H1 of 2026. Also, we only had one de novo, and that was Loganville, Georgia, that moved from new store to same store in Q3. I will note that we have 90 beds moving into same store in Q4, and another 150 in Q1 of 2027.

Speaker #7: So what we've demonstrated is that the pilot is working. And as Pat outlined, we're looking forward to extending that across stroke in all of our hospitals and then bringing more hospitals into the fold from a pilot perspective.

Doug Coltharp: In terms of bed additions and new hospitals, as we mentioned previously, bed additions in 2026 were also heavily weighted towards the H2 of the year. Q3 benefited from only 54 beds added to existing hospitals in the H1 of 2026. Also, we only had one de novo, and that was Loganville, Georgia, that moved from new store to same store in Q3. I will note that we have 90 beds moving into same store in Q4, and another 150 in Q1 of 2027.

Speaker #7: In terms of bed additions and new hospitals, as we mentioned previously, bed additions in 2026 were also heavily weighted towards the second half of the year.

Speaker #7: Q3 benefited from only 54 beds added to existing hospitals in the first half of '26. And also, we only had one de novo, and that was Loganville, Georgia, that moved from new-store to same-store in Q3.

Speaker #7: I'll note that we have 90 beds moving into same-store in Q4, and another 150 in Q1 of '27. And then something we haven't talked about a lot but that's evident, I think, to some degree in our overall patient mix is there is some impact that is happening across the 89-team markets.

Doug Coltharp: Something we have not talked about a lot, but it is evident, I think, to some degree in our overall patient mix, is there is some impact that is happening across the 80/19 markets. In Q3, we saw knee and hip replacement actually decline 3.6%. These are small categories for us. Cardiac declined about 0.7%. Not all TEAM markets are reacting the same. In those markets, we are having a lot of success substituting higher acuity and/or VA CCN patients for these lower acuity patients that may be subject for TEAM. While it may not be a one for one change from a volume perspective, what we are seeing in those markets is that the move to the higher acuity patients and the move to the VA CCN patients is generating higher revenue and EBITDA.

Speaker #7: And so in Q3, we saw knee and hip replacement actually decline 3.6%. And these are small categories for us. And cardiac decline about 0.7%.

Doug Coltharp: These are small categories for us. Cardiac declined about 0.7%. Not all TEAM markets are reacting the same. In those markets, we are having a lot of success substituting higher acuity and/or VA CCN patients for these lower acuity patients that may be subject for TEAM. While it may not be a one for one change from a volume perspective, what we are seeing in those markets is that the move to the higher acuity patients and the move to the VA CCN patients is generating higher revenue and EBITDA.

Speaker #7: Now, not all teams markets are reacting the same. And in those markets, we're having a lot of success substituting higher acuity and/or VACCN patients for these lower acuity patients that may be subject for team.

Speaker #7: And why it may not be a one-for-one change, from a volume perspective, what we're seeing in those markets is that the move to the higher acuity patients and the move to the VACCN patients has generating higher revenue and EBITDA.

AJ Rice: Okay. That is great. Thanks. I would, maybe as my follow-up, just ask, I know you are now down to 1.8x net leverage. I think, you previously said that it would not necessarily make sense to go below 2x. Should we think of capital deployment from here leaning into share repurchases, dividends, anything else, any comment you want to make along those lines?

Speaker #5: Okay, that's great, thanks. I would maybe, as my follow-up, just ask—I know you're now down to 1.8 times net leverage. I think you've previously said that it wouldn't necessarily make sense to go below two times.

Speaker #5: Should we think of capital deployment from here leading into share repurchases, dividends, anything else? Any comment you want to make along those lines?

Doug Coltharp: Yeah, I think that the capital allocation framework is going to be relatively consistent. You will probably see modest, occasional, or periodic increases in the dividends, so that is not going to consume a lot of that capacity. Pat mentioned earlier that as we think about an accelerating pipeline for both small format hospitals and for de novo openings, particularly with the attractiveness of North Carolina as just an example, that we are likely to see our discretionary CapEx begin to increase. And that is still going to leave capacity, but while maintaining a very favorable leverage target for increased share repurchase activity. So we like the combination of those things.

Speaker #7: Yeah, I think that the capital allocation framework is going to be relatively consistent. You'll probably see modest, occasional, or periodic increases in the dividends.

Speaker #7: So that's not going to consume a lot of that capacity. Pat mentioned earlier that as we think about an accelerating pipeline for both small-format hospitals and for de novo openings, particularly with the attractiveness of North Carolina as just an example, that we're likely to see our discretionary capex begin to increase and that's still going to leave capacity but while maintaining a very favorable leverage target for increased share repurchase activity.

Doug Coltharp: Pat mentioned earlier that as we think about an accelerating pipeline for both small format hospitals and for de novo openings, particularly with the attractiveness of North Carolina as just an example, that we are likely to see our discretionary CapEx begin to increase. And that is still going to leave capacity, but while maintaining a very favorable leverage target for increased share repurchase activity. So we like the combination of those things.

Speaker #7: So, we like the combination of those things.

Operator: We will take our next question from Jared Haase with William Blair. Your line is open.

Speaker #1: We'll take our next question from Jared Haass with William Blair. Your line is open.

Doug Coltharp: Morning, Jared.

Mark Tarr: Morning, Jared.

Speaker #8: Morning, Jared.

Speaker #7: Morning, Jared.

Jared Haase: Morning. Thanks for taking all the questions here. Maybe I will ask one on the current mix of your beds between single occupancy and double. I know you had this shift towards more single over the last couple of years. Just wanted to get an update on where that stands today, and then based on what you have in the pipeline, where you think that could trend over the next couple of years.

Speaker #3: Morning. Thanks for taking all the questions here. Maybe I'll ask one on the current mix of your beds between single occupancy and double. I know you kind of had this shift towards more single over the last couple of years.

Speaker #3: Just wanted to get an update on where that stands today and then based on what you have in the pipeline, where you think that could trend over the next couple of years.

Doug Coltharp: Yeah. So at the end of Q3, we were at 58%. That compares, if you go all the way back to 2020, at 41%. So 58% were private. Essentially all of the capacity that we are bringing on in all three modalities, bed additions, de novos, and small format hospitals, is going to be 100% single occupancy. So that number will continue to push up. We will get some benefit of that here in Q4 because of the number of bed additions and new hospitals that we have coming on board. So that number will be higher when we report it for Q4.

Speaker #7: Yeah, so at the end of the third quarter, we were at 58%. That compares, if you go all the way back to 2020, to 41%.

Speaker #7: So 58% were private essentially all of the capacity that we're bringing on in all three modalities. Bed additions, de novos, and small-format hospitals is going to be 100%.

Speaker #7: Single occupancy. So that number will continue to push up. And we'll get some benefit of that here in the fourth quarter because of the number of bed additions and new hospitals that we have coming on board.

Speaker #7: So that number will be higher when we report it for Q4.

Jared Haase: Okay. Very helpful. I appreciate all the details on the Medicare Advantage admit and appeal strategy. I realize it is still relatively early with the pilots, but just given the success you have seen so far, and then you are thinking around how you can expand that to other conditions and other hospitals across the portfolio. I guess, when we think about the impact to the model, are there any guardrails that you would frame for us in terms of what the actual net impact could be on conversion rate or, I guess, ultimately, volume growth within that cohort over the next several years?

Speaker #3: Okay. Very helpful. And then I appreciate all the details on the Medicare Advantage admit-and-appeal strategy. I realize it's still relatively early with the pilots, but just given the success you've seen so far and then you're thinking around how you can expand that to other conditions and other hospitals across the portfolio, I guess when we think about the impact of the model, are there any guardrails that you would sort of frame for us in terms of what the actual net impact could be on conversion rate or, I guess, ultimately, volume growth within that cohort over the next several years?

Jared Haase: I guess, when we think about the impact to the model, are there any guardrails that you would frame for us in terms of what the actual net impact could be on conversion rate or, I guess, ultimately, volume growth within that cohort over the next several years?

Doug Coltharp: Well, generally speaking, we think it is positive. A, because we are anniversarying the more challenging pre-authorization from the MA plans that began in Q4 of last year, and that has proven to be an effective tool. Because even beyond what we are experiencing in these categories with regard to denial rates pre that dip in Q4 of last year, we are seeing higher success rates. All of that said, it is not going to happen in a vacuum, and so we believe it is a tailwind. In terms of quantifying it, that is yet to be determined.

Speaker #7: Well, generally speaking, we think it's positive. A, because we're anniversarying the more challenging pre-authorization from the MA plans that began in Q4 of last year and that's proven to be an effective tool because even beyond what we were experiencing in these categories with regard to denial rates, pre-that dip in Q4 of last year, we're seeing higher success rates.

Speaker #7: All of that said, it's not going to happen in a vacuum. And so we believe it is a tailwind in terms of quantifying it.

Speaker #7: That's yet to be determined.

Pat Tuer: Hey, Jared, this is Pat. We are in the process now of, we have added resources since we started the pilot. We are adding a good number of FTEs that are going to help us as we scale this throughout the organization. We are putting the structure in place to be able to go a little bigger here.

Speaker #6: Hey, Jared, this is Pat. We're in the process now of we've added resources since we've started the pilot. We're adding a good number of FTEs that are going to help us as we scale this throughout the organization.

Speaker #6: But we're putting the structure in place to be able to go a little bigger here.

Operator: We will take our next question from Raj Kumar with Stephens. Your line is open.

Speaker #1: We'll take our next question from Raj Kumar with Stevens. Your line is open.

Doug Coltharp: Morning, Raj.

Speaker #8: Morning, Raj.

Raj Kumar: Hey, good morning. I just wanted to touch back on RCD. As I look at the Alabama cycle through reports, the claims activity coming down by 25% relative to the pre-RCD baseline, but looking at your guys' results, fee for service, still pretty strong. I would love to reconcile your experience in that Alabama program across these three cycles, and more specifically, I guess, where your initial affirmation rates are, maybe where your appeal rates are as well, and maybe helping us extrapolate to this more expanded RCD program. Any details there will be helpful.

Speaker #9: Hey, good morning. Maybe I just wanted to touch back on RCD as I look at the Alabama cycle-through reports. The claims activity is coming down by 25% relative to the pre-RCD baseline.

Speaker #9: But kind of looking at you guys' results, fee-for-service still pretty strong. So would love to kind of reconcile kind of your experience in that kind of Alabama program across these three cycles and more specifically, I guess, kind of where your initial affirmation rates are kind of maybe where your appeal rates are as well and maybe helping us extrapolate to this more expanded RCD program.

Raj Kumar: I would love to reconcile your experience in that Alabama program across these three cycles, and more specifically, I guess, where your initial affirmation rates are, maybe where your appeal rates are as well, and maybe helping us extrapolate to this more expanded RCD program. Any details there will be helpful.

Speaker #9: Any details there would be helpful.

Doug Coltharp: Well, it is hard to extrapolate any of our experience across the expanded program because Palmetto in particular has never been asked to handle this volume of claims. We do not know if it is going to be the same reviewers, we do not know if it is going to be under the direction of the same medical director, we do not know whether they are going to be using subcontractors. We do not know if the program is ultimately going to be phased in, et cetera. What we do have a high degree of confidence in is that we are admitting the right kind of patients, and we are providing the appropriate documentation. Again, as this extension begins on, assuming it begins across all of these 75 hospitals on 1 January, we will be prepared administratively to do our part.

Speaker #7: Well, it's hard to extrapolate any of our experience across the expanded program, because Palmetto, in particular, has never been asked to handle this volume of claims.

Speaker #7: And so we don't know if it's going to be the same reviewers. We don't know if it's going to be under the direction of the same medical director.

Speaker #7: We don't know whether they're going to be using subcontractors. We don't know if the program is ultimately going to be phased in, etc. What we do have a high degree of confidence in is that there's that we are admitting the right kind of patients, and we are providing the appropriate documentation.

Doug Coltharp: We do not know if the program is ultimately going to be phased in, et cetera. What we do have a high degree of confidence in is that we are admitting the right kind of patients, and we are providing the appropriate documentation. Again, as this extension begins on, assuming it begins across all of these 75 hospitals on 1 January, we will be prepared administratively to do our part.

Speaker #7: And again, as this extension begins on assuming it begins across all of these 75 hospitals, on January 1st, we will be prepared administratively to do our part.

Doug Coltharp: The target affirmation rate in cycle 1 is going to be 80%, and we have a very high degree of confidence that all of our hospitals are going to get over that 80% target affirmation rate. If they do, beginning 1 July, we can move to a 5% spot check. That is not something that we have experience with to date, because to this point, either because we were in cycle 1 in the other states that just came out, which was a requirement like California and Texas, or because we elected to stay for various reasons on 100% prepayment claim review in Alabama. We have not had experience with the 5% spot check. But the math will tell you that the impact is going to be less, and the administrative burden will be less.

Speaker #7: And the target affirmation rate in cycle one is going to be 80%. And we have a very high degree of confidence that all of our hospitals are going to get over that 80% target affirmation rate.

Speaker #7: And if they do beginning July 1st, we can move to a 5% spot check. That is not something that we have experience with to date because to this point, either because we were in cycle one in the other states that just came out, which was a requirement like California and Texas or because we elected to stay for various reasons on 100% prepayment claim review in Alabama, we haven't had experience with the 5% spot check.

Doug Coltharp: That is not something that we have experience with to date, because to this point, either because we were in cycle 1 in the other states that just came out, which was a requirement like California and Texas, or because we elected to stay for various reasons on 100% prepayment claim review in Alabama. We have not had experience with the 5% spot check. But the math will tell you that the impact is going to be less, and the administrative burden will be less.

Speaker #7: But the math will tell you that the impact is going to be less and the administrative burden will be less. And so again, we think if there's volatility in the bad debt number that arises out of the rollout to these 75 incremental hospitals, it's going to be contained and it's likely going to be contained to the first half of the year.

Doug Coltharp: Again, we think if there is volatility in the bad debt number that arises out of the rollout to these 75 incremental hospitals, it is going to be contained, and it is likely going to be contained to the H1. It is important to note, none of the coverage requirements, none of the patient criteria under RCD are any different than they have been under the audit programs that we have been subject to for an extended period of time, and that have informed our historical bad debt in this recent range of 2% to 2.5%. So there is no reason to believe if things settle in, that we are going to settle in at a bad debt number that differs in any material way from that which we have experienced historically.

Speaker #7: It's important to note none of the coverage requirements, none of the patient criteria under RCD are any different than they have been under the audit programs that we have been subject to for an extended period of time, and that have informed our historical bad debt in this recent range of 2 to 2 and a half percent.

Doug Coltharp: none of the coverage requirements, none of the patient criteria under RCD are any different than they have been under the audit programs that we have been subject to for an extended period of time, and that have informed our historical bad debt in this recent range of 2% to 2.5%. So there is no reason to believe if things settle in, that we are going to settle in at a bad debt number that differs in any material way from that which we have experienced historically.

Speaker #7: So there's no reason to believe that things settle in that we're going to settle in at a bad debt number that differs in any material way from that which we've experienced historically.

Raj Kumar: Got it. Maybe just following up on that, I guess when I think about maybe some of the more independent IRFs, and maybe some behavioral changes around maybe not appealing or not admitting IRF eligible patients that might be on the fringe of eligibility, I guess, have you maybe experienced any market share gain dynamics from that, or any favorability as I think about your administrative working power versus maybe an independent mom and pop IRF?

Speaker #9: Got it. Maybe just following up on that. I guess when I think about maybe some of the more independent IRFs and maybe some behavioral changes around maybe not appealing or not admitting IRF-eligible patients that might be on the fringe of eligibility, I guess, have you maybe experienced any market share gain dynamics from that or any favorability as I kind of think about kind of your administrative working power versus maybe an independent mom-and-pop IRF?

Doug Coltharp: We don't think we're admitting patients who are on the fringe of eligibility. We think that the patients that we admit clearly meet IRF admission requirements.

Speaker #7: We don't think we're admitting patients who are on the fringe of eligibility. We think that the patients that we admit clearly meet IRF admission requirements.

Pat Tuer: Yeah, this is Pat. I would just add, I sit on the board of AMRPA, which is the trade association for inpatient rehab providers, and I think, not only Encompass, but the other providers within AMRPA have all done a really nice job with RCD. It hasn't shifted our admission practices. We're taking the same patients that we did before, and to my knowledge, the other providers are as well. I think if anything, administrative burden aside, we're proud of the fact that this has demonstrated such a strong record of compliance within our company and the industry.

Speaker #6: Yeah. This is Pat. I would just add I sit on the board of AMRPA, which is the Trade Association for Inpatient Rehab Providers. And I think not only encompass, but the other providers within AMRPA have all done a really nice job with RCD.

Speaker #6: And it hasn't shifted our admission practices. I mean, we're taking the same patients that we did before and to my knowledge, the other providers are as well.

Speaker #6: So I think if anything, administrative burden aside, we're proud of the fact that this has demonstrated such a strong record of compliance within our company and the industry.

Operator: Thank you. At this time, there are no further questions in queue. I will now turn the meeting back to Mark Miller for any additional or closing remarks.

Speaker #1: Thank you. At this time, there are no further questions in queue. I will now turn the meeting back to Mark Miller for any additional or closing remarks.

Mark Miller: Thank you, operator. If anyone has additional questions, please call me at 205-970-5860. Thank you again for joining today's call.

Speaker #2: Thank you, operator. If anyone has additional questions, please call me at 205-970-5860. Thank you again for joining today's call.

Operator: Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.

More EHC earnings call transcripts

Browse all earnings call transcripts

Q3 2026 Encompass Health Corp Earnings Call

Request TrialDemo

Event Details

Encompass Health

EHC

Earnings

Q3 2026 Encompass Health Corp Earnings Call

Thursday, October 29th, 2026 at 2:00 PM

Open Event Documents

Search Transcript

Enter a search term to find quotes

Encompass Health

Earnings

Q3 2026 Encompass Health Corp Earnings Call

EHC

Thursday, October 29th, 2026 at 2:00 PM

Transcript

No Transcript Available

No transcript data is available for this event yet. Transcripts typically become available shortly after an earnings call ends.

Want AI-powered analysis? Try AllMind →

Earnings analysis guides

Methods for extracting KPIs and checking source support when reviewing an earnings call.

Q3 2025 Encompass Health Corp Earnings CallOctober 30, 2025
Q4 2025 Encompass Health Corp Earnings CallFebruary 6, 2026
Q1 2026 Encompass Health Corp Earnings CallMay 1, 2026
Q2 2026 Encompass Health Corp Earnings CallAugust 6, 2026

Browse all earnings calls